CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial

CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial

302037

CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial

Clene’s investigational oral therapy CNM-Au8 improved energy metabolism in the brain of adults with relapsing-remitting multiple sclerosis (RRMS), according to top-line results from the REPAIR-MS trial. This open-label Phase 2 pilot study (NCT03993171), taking place in Texas, is running in parallel with REPAIR-PD, another Phase 2 open-label trial showing similar results in people with Parkinson’s disease, a neurodegenerative disease caused by the loss of certain brain cells. CNM-Au8, also being developed for the progressive neurological…

You must be logged in to read/download the full post.